By Deena Beasley May 5 (Reuters) - Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has ...
Researchers at Karolinska Institutet, in collaboration with colleagues at The Scripps Research Institute and Emory University ...
Gilead Sciences' twice-yearly HIV prevention injection Yeztugo has gained users since its June launch, but adoption is slowed by insurance coverage gaps, patient preference for pills, and concerns ...
Scientists have designed a DNA scaffold that carries HIV vaccine proteins into the body and sharpens the immune response against the virus. One of the biggest hurdles in developing an HIV vaccine is ...
SEATTLE — There is still no cure for HIV, but researchers have made huge strides to treat and prevent the infection. This month, the FDA approved a preventative drug that's being called a ...
Gilead Sciences’ twice-yearly HIV prevention injection Yeztugo has seen rising uptake since its U.S. launch, but patients still face insurance coverage gaps and cost-sharing barriers. While more than ...
Deploying lenacapavir will require rethinking who delivers HIV prevention, how it is financed, and what policy infrastructure must be built, and rebuilt, to match the science.
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for ...
Researchers at Karolinska Institutet, in collaboration with colleagues at The Scripps Research Institute and Emory University, have developed a new vaccine strategy that has generated antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results